A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation

Among brain tumors, the BRAF V600E mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). This oncogenic mutation is also detected in ~5 % of other pediatric low-grade gliomas (LGGs) including pilocytic astrocytomas (PAs) and diffuse astrocytomas. In t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta neuropathologica 2015-10, Vol.130 (4), p.575-585
Hauptverfasser:	Ho, Cheng-Ying, Mobley, Bret C., Gordish-Dressman, Heather, VandenBussche, Christopher J., Mason, Gary E., Bornhorst, Miriam, Esbenshade, Adam J., Tehrani, Mahtab, Orr, Brent A., LaFrance, Delecia R., Devaney, Joseph M., Meltzer, Beatrix W., Hofherr, Sean E., Burger, Peter C., Packer, Roger J., Rodriguez, Fausto J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Factors Brain cancer Brain Neoplasms - epidemiology Brain Neoplasms - genetics Brain Neoplasms - pathology Brain Neoplasms - therapy Brain research Child Child, Preschool Cohort Studies Cyclin-Dependent Kinase Inhibitor p16 - genetics Diencephalon - pathology Disease-Free Survival Female Follow-Up Studies Gene mutation Genetic aspects Glioma - epidemiology Glioma - genetics Glioma - pathology Glioma - therapy Gliomas Hospitals Humans Infant Kinases Magnetic Resonance Imaging Male Medical prognosis Medicine Medicine & Public Health Mutation Neoplasm Grading Neurosciences Original Paper Pathology Pediatrics Proto-Oncogene Proteins B-raf - genetics Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among brain tumors, the BRAF V600E mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). This oncogenic mutation is also detected in ~5 % of other pediatric low-grade gliomas (LGGs) including pilocytic astrocytomas (PAs) and diffuse astrocytomas. In the current multi-institutional study of 56 non-PXA/non-GG diencephalic pediatric LGGs, the BRAF V600 mutation rate is 36 %. V600-mutant tumors demonstrate a predilection for infants and young children (
ISSN:	0001-6322 1432-0533
DOI:	10.1007/s00401-015-1467-3